Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (C...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Shoushtari, Alexander N., Friedman, Claire F., Navid-Azarbaijani, Pedram, Postow, Michael A., Callahan, Margaret K., Momtaz, Parisa, Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2017
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833656/
https://ncbi.nlm.nih.gov/pubmed/28817755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2391
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items